1 November 2020 in Journal of Catalysis
30 October 2020 in Chemistry – A European Journal
The first dicobalt(III) μ2‐peroxo N‐heterocyclic carbene (NHC) complex is reported. It can be quantitatively generated from a cobalt(II) compound bearing a 16‐membered macrocyclic tetra‐NHC ligand via facile activation of dioxygen from air at ambient conditions. The reaction proceeds via an end‐on superoxo intermediate as demonstrated by EPR studies and DFT. The peroxo moiety can be cleaved upon addition of acetic acid, yielding the corresponding CoIII acetate complex going along with H2O2 formation. In contrast, both CoII and CoIII complexes are also studied as catalysts to utilize air for olefin and alkane oxidation reactions; however, not resulting in product formation. The observations are rationalized by DFT‐calculations, suggesting a nucleophilic nature of the dicobalt(III) μ2‐peroxo complex. All isolated compounds are characterized by NMR, ESI‐MS, elemental analysis, EPR and SC‐XRD.
19 September 2024 in Organometallics
This work presents the synthesis of five new functionalized (benz)imidazolium N-heterocyclic (NHC) ligands (L) and four new (benz)imidazole silver(I) NHC (Ag(I)-NHC) complexes of mononuclear [Ag(L)2](PF6) or binuclear [Ag2(L)2](PF6)2 type. The complexes have been fully characterized, including single crystal X-ray diffraction of three new structures. The complexes and their corresponding free NHC ligands have been screened against breast cancer and noncancerous cell lines, showing the mononuclear benzimidazole complex has the highest activity, while the binuclear benzimidazole complex has the highest cancer cell selectivity. The silver uptake was measured by ICP-MS and highlights a strong link between cytotoxicity and cellular uptake. DNA interaction studies, molecular docking, and evaluation of reactive oxygen species (ROS) have been conducted for the most promising complexes to identify modes of action. Overall, the binuclear benzimidazole complex is the most selective and promising candidate against the MDA-MD-231 (breast cancer) cell line and has potential to be developed for treatment of late-stage breast cancers.
11 January 2021 in Catalysis Science & Technology
Pivotal degradation pathways of the most active non-heme iron epoxidation catalyst to date are investigated in detail. In-depth HR-ESI-MS and NMR spectroscopy decomposition studies and comparative catalytic experiments exclude the generally accepted literature paths of μ2-oxo bridged FeIII–O–FeIII dimer formation and methylene bridge oxidation. Instead, the Fe–NHC bond has been identified as the “weak spot”. It is shown that direct oxidation of one of the carbenes (ImCO) results in its de-coordination and induces protonation of the other NHC moieties, thus completely deactivating the catalyst. Evidence for protonation prior to carbene oxidation has not been found in this study.
22 August 2025 in Inorganic Chemistry
Four new charged iridium(III) 1,2,3,4,5-pentamethylcyclopentadienyl (Cp*) complexes, 1-4, of the type [Cp*Ir(L1-4)(PTA)](PF6) (where L1-4 = functionalized β-ketoiminate ligands and PTA = 1,3,5-triaza-7-phosphaadamantane), have been successfully synthesized and characterized. Single crystal X-ray crystallographic data have been obtained for all compounds and confirm a typical pseudo-octahedral half-sandwich geometry. Cytotoxicity values have been determined against a range of cancerous and noncancerous cell lines and highlight high cytotoxicity and selectivity toward breast cancers. Among these compounds, the unfunctionalized β-ketoiminate Ir(III) complex (1) emerged as the most promising candidate, demonstrating activity that was comparable to or exceeded that of cisplatin, especially after 24 h against the triple-negative MDA-MB-231 cell line. Morphological and molecular analyses confirmed that 1 triggers apoptotic cell death, involving caspase activation and PARP cleavage, which is consistent with its DNA-damaging characteristics, highlighting the future anticancer potential of compound 1.
14 November 2024 in ChemBioChem
A library of ferrocenyl β‐diketonate compounds with varying degrees of aromatic functionality have been synthesized and fully characterized. This includes cyclic voltammetry and the analysis of four new structures by single crystal X‐ray diffraction. The compounds cytotoxic potential has been determined by MTT screening against pancreatic carcinoma (MIA PaCa‐2), ovarian adenocarcinoma (A2780), breast adenocarcinomas (MDA‐MB‐231 and MCF‐7) and normal epithelial retinal (ARPE‐19). The compounds show a general trend, where increasing the number of aromatic rings in the molecule yields an increase in cytotoxicity and follows the trend anthracenyl>naphthyl>phenyl>methyl. The compounds are particularly sensitive to the triple negative cancer cell line MDA‐MB‐231, and the potential modes of action have been studied by production of reactive oxygen species using fluorescence microscopy and cell morphology using Scanning Electron Microscopy. All assays highlight the ferrocenyl β‐diketonate with an anthracenyl substituent to be the lead compound in this library. The decomposition of this compound was also observed within cells, yielding a cytotoxic fluorescent molecule, which has been visualized by confocal microscopy.